Targovax ASA: Third quarter 2018 results
Oslo, Norway, 1 November 2018 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its third quarter 2018 results.Targovax's management will host an online presentation for investors, analysts and the press at 08:45 CET. The presentation in Norwegian can be followed here , or at: https://www.facebook.com/AXExposure/videos/279295392691286/ An English version can be found on Targovax Events & Presentations